Epigenomics AG (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation, announced today the successful completion of a 605 patient study validating three of its proprietary DNA methylation markers as clinically useful indicators of prostate cancer aggressiveness. Epigenomics, which during 2005 prepared to initiate its own development of molecular pathology products, also announced the development of the test as its own product, following Roche Diagnostics’ decision to discontinue the collaborative development of the prostate cancer molecular classification test and to not maintain their option rights to an exclusive license.
